Some examples of these trials are the TULIP phase III trial (NCT03262935) in advanced or metastatic BC settings, a phase I/Ib trial in HER2-low tumors (ORR ranging from 28% to 40%, depending on HR expression) (NCT04602117) [48], and a phase I trial in patients with solid tumors, in which SYD985 is administered in combination with niraparib (NCT04235101) [37]. Here, ERBB2 is linked to breast cancer.